You just read:

Milestone Pharmaceuticals Announces Etripamil Phase 2 Clinical Program Success for the Treatment of Paroxysmal Supraventricular Tachycardia

News provided by

Milestone Pharmaceuticals

11 May, 2017, 09:00 ET